Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO THE PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week, we dive into one of biotech’s strangest and most important emerging tensions: just as regulators are opening the door to more flexible, mechanism-driven approvals for individualized therapies in ultra-rare disease, the field is being hit with fresh reminders that elegant biology is not the same as predictable biology. We unpack what the FDA’s new “plausible mechanism” framework really signals, why recent gene therapy setbacks at companies like Sarepta and Capsida expose the limits of platform thinking, and how biotech may be shifting away from the old dream of scalable, programmable medicine toward something messier, more bespoke, and far more uncertain. At the center of the episode is a deeper question: in an era where the science looks increasingly legible but the risks remain stubbornly human, what exactly should count as enough evidence to believe?
📣🎙️ TODAY’S PODCAST:
[ 0:34 ] Desperate patience collide
[ 1:20 ] Evidence era shifts
[ 2:13 ] Plausible mechanism framework
[ 4:38 ] CHOP and Penn
[ 7:24 ] Illusion of the platform
[ 7:29 ] Sarepta clinical hold
[ 10:32 ] Capsida cerebral edema
[ 12:25 ] Mechanistic coherence breaks
[ 13:24 ] New medical economy
[ 15:49 ] New social contract
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
